[6] Turing Pharmaceuticals was launched in February 2015 by Martin Shkreli with the acquisition of three major assets from an orphan drug developer called Retrophin: an intranasal formulation of ketamine, an oxytocin nasal solution, and Vecamyl.

[9] Shkreli resigned as Turing Pharmaceuticals' CEO on 18 December 2015, following his arrest on charges of defrauding investors in his former hedge fund.

[13] Despite these partial rollbacks to the initial price increase, according to February 2, 2016, memo from Representative Elijah Cummings to the United States House Committee on Oversight and Government Reform, since Turing's acquisition to the rights in Daraprim, the drug has gone from being affordable and readily available to being prohibitively expensive.

[14] In January 2020 the FTC filed a case against Vyera "alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim".

The product had gained FDA approval in 1960 to assist in initial postpartum milk ejection, but was discontinued by Sandoz's successor company, Novartis, in 1997 because of poor sales.

Retrophin had licensed the product from Novartis in December 2013 in order to bring it back to the market for postpartum milk ejection as well as look into its use in the treatment of schizophrenia and autism.